Home > Insider Trading > Filing (0001209191-18-030691)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1001233	Sangamo Therapeutics Inc	SGMO	Biological Products, (No Disgnostic Substances) (2836)	680359556

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1697802	Kathy Yi	C/O Sangamo Therapeutics, Inc. Point Richmond Tech Ctr, 501 Canal Blvd. Richmond CA 94804	Svp & Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-05-15	5,000	$4.55	12,250	No	4	M	Direct
Common Stock	Disposition	2018-05-15	5,000	$15.38	7,250	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2018-05-15	5,000	$0.00	5,000	$4.55

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
185,000		2027-02-27	No	4	M	Direct

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017.
The price reported is a weighted average price. The shares were sold at prices ranging from $15.20 to $15.55. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Represents 7,250 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date.
One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.